Figure 1: In GBM cells, ISCADOR Q changes the expression of cancer associated genes. (a) PCR-based microarray expression analysis. LNT-229 cells were treated with ISCADOR Q (100 μg/mL) or were left untreated. 24 h later, the cells were harvested, mRNA was prepared, reverse transcribed into cDNA and used for microarray-based expression analysis on a panel of 96 migration-/invasion-angiogenesis-involved genes. The best downregulated genes with a threshold are shown. (b) RT-PCR-based validation of differentially regulated genes detected in (a) at 12 or 24 h of ISCADOR Q treatment (, SEM). (c) TGF- ELISA of ISCADOR Q treated LNT-229 cells. The cells were treated with ISCADOR Q (100 μg/mL, 24 h) followed by incubation in serum-free medium for 48 h. Supernatants were harvested and TGF-β 1 or TGF-β 2 was quantified using ELISA (, SEM). (d) The cells were treated with ISCADOR Q (100 μg/mL, 12 or 24 h). Supernatants were harvested 48 h later. Angiopoietin-1 content was analyzed using ELISA (, SEM). (e) The cells were treated as in (c). Supernatants were harvested and VEGF content was analyzed using ELISA (, SEM). (f) Contingency table analysis of the PCR-based microarray expression data together with the corresponding genes of the REMBRANDT database. Nominal scaled response variable (genes significantly up- (1), non- (0), or down- (−1) regulated in glioblastomas versus normal brain tissue expression pattern in the REMBRANDT database) and nominal explanatory variable (same gene up- or downregulated in our PCR-based microarray expression analysis after ISCADOR treatment) were analysed and subsequently tested by the likelihood ratio test ().